EyePoint Pharmaceuticals Inc expected to post a loss of 66 cents a share - Earnings Preview

EyePoint

05/05/2025 14:25

EyePoint Pharmaceuticals Inc EYPT.OQ EYPT.O is expected to show a fall in quarterly revenue when it reports  results on May 7 for the period ending March 31 2025

The Watertown Massachusetts-based  company is expected to report a 31.7% decrease in revenue to $7.977 million from $11.68 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.

​LSEG's mean analyst estimate for EyePoint Pharmaceuticals Inc is for a loss of 66 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 4.5% in the last three months. ​

Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc is $30.50​, above​ its last closing price of $7.30. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.47
-0.50
-0.64
Missed
-27.7
Sep. 30 2024
-0.56
-0.56
-0.54
Beat
3
Jun. 30 2024
-0.51
-0.52
-0.58
Missed
-10.5​
Mar. 31 2024
-0.42
-0.42
-0.55
Missed
-32.2
​​Dec. 31 2023
-0.46
-0.49
-0.33
Beat
32.1
Sep. 30 2023
-0.54
-0.51
-0.33
Beat
35.7​
Jun. 30 2023
0.68
0.60
-0.61
Missed
-201.9
Mar. 31 2023
-0.68
-0.68
-0.56
Beat
18

This summary was machine generated May 5 at 13:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)